News Release
Kairos Pharma (NYSEAmerican: KAPA): Advancing New Strategies to Overcome Cancer Treatment Challenges
KAPA
The global oncology landscape is on the brink of transformation, with cancer cases expected to rise sharply, particularly in lower-income countries, where the number of new cases could soar to 32 million annually by 2050. This growing demand for cancer treatments has driven global spending on oncology medicines to $223 billion in 2023, with a projected increase to $409 billion by 2028. The launch of 25 novel oncology drugs in 2023, along with over 2,000 new clinical trials, highlights a dynamic period of innovation in the sector. Breakthrough therapies, including cell and gene therapies, antibody-drug conjugates, and radioligand treatments, show significant promise but remain unevenly accessible. As oncology treatments continue to evolve at a rapid pace, this environment presents a unique window of opportunity for investors to explore emerging biopharma companies, which are positioned to lead the charge in addressing unmet medical needs in cancer care. Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company based in Los Angeles, is steadily building a presence in the oncology space. Focusing on therapies aimed at overcoming cancer drug resistance and immune suppression, Kairos has developed a promising pipeline that could attract attention. Among its most notable candidates is ENV105, a therapy designed to target the mechanisms that allow tumors to evade treatment. With ongoing clinical trials and a recent IPO, Kairos Pharma (KAPA) shows potential as an emerging player in biotechnology, particularly as it continues to develop personalized cancer treatments. Exploring New Avenues in Cancer Treatment with ENV105 At the forefront of Kairos Pharma's mission is ENV105, a groundbreaking therapy aimed at reversing drug resistance in cancer patients. This drug distinguishes itself from traditional treatments by targeting the mechanisms that allow tumors to evade existing therapies. Mechanism of Action: ENV105 works by inhibiting the CD105 protein, which plays a critical role in the Bone Morphogenetic Protein (BMP) pathway. Unlike many cancer treatments that focus on blocking Tumor Necrosis Factor (TNF), ENV105 addresses the BMP pathway, which can contribute to increased tumor resistance. By disrupting this pathway, ENV105 enhances the effectiveness of existing cancer treatments. Biomarker Advantage: A significant aspect of ENV105 is its associated biomarker, which can predict patient responses before treatment begins. This capability allows for a more personalized approach, ensuring that patients who are most likely to benefit from the therapy are identified upfront, potentially increasing treatment success rates. Clinical Trial Successes The results from recent clinical trials are promising. In studies involving ENV105, 62% of patients experienced disease stabilization or regression after just two months of treatment—a remarkable outcome compared to the typical response rates seen in similar populations. Additionally, ENV105 has shown efficacy in enhancing the effects of existing therapies for both prostate and lung cancers, two of the most prevalent cancer types. Recent Developments and Partnerships Kairos Pharma is making significant strides in its clinical trials. The company recently dosed its first patients in a Phase 1 trial combining ENV105 with osimertinib for non-small cell lung cancer. This trial aims to evaluate the safety and tolerability of the combination, while a concurrent Phase 2 trial tests ENV105 alongside apalutamide for treating castrate-resistant prostate cancer. John Yu, CEO of Kairos Pharma, emphasizes the company’s commitment to addressing urgent medical needs: “The initiation of these trials speaks to the dedication of the Kairos team to develop therapies for today’s unmet medical needs.” Further enhancing its prospects, Kairos Pharma has partnered with PreCheck Health Services to develop companion biomarkers that will identify which patients are most likely to benefit from ENV105. This collaboration aims to incorporate advanced molecular diagnostics into clinical practice, allowing for better patient selection and monitoring. On September 16, 2024, Kairos Pharma made its debut on the NYSE American under the ticker symbol “KAPA,” successfully raising $6.2 million through its initial public offering. The proceeds will be vital for funding ongoing clinical trials and advancing its diverse pipeline, which includes ENV105 and other innovative candidates like KROS 101. Conclusion With its focus on reversing cancer drug resistance and improving immune response, KAPA is poised to make an impact in oncology. As Kairos Pharma continues to advance its trials and develop personalized cancer therapies, it stands on the brink of potentially revolutionizing cancer treatment. For those looking to invest in a company with a bright future in biotechnology, Kairos Pharma is one for the watchlist. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Cambridge Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 Mark@razorpitch.com Company Website http://razorpitch.com
October 14, 2024 06:00 AM Eastern Daylight Time
News Release
